SERENITYNCT07760818
A Study to Assess Efficacy and Safety of Efgartigimod in Adults With Sjogren's Disease-associated Sensorimotor Polyneuropathy or Sensory Polyneuropathy (SERENITY)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 10 words
- Trial sites expanded: 0 → 3 locations
- Start date changed from estimate of Aug 14, 2026 to Oct 9, 2026
- Secondary endpoints: details revised at 10 of 13 entries
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score at the end of Part A
Timeframe: Up to 48 weeks
Secondary (13)
Change from baseline in modified Toronto Clinical Neuropathy Score (mTCNS) total score over time
Change from baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) total score at the end of part A and over time
Change from baseline in clinical EULAR Sjögren's Syndrome Disease Activity Index (clinESSDAI) score at the end of part A and over time
Change from baseline in EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score at the end of part A and over time
Proportion of participants with low disease activity (clinESSDAI < 5) at the end of part A and over time
Show 8 moreShow less
Incidence of AEs
Change from baseline in Neuropathic Pain Questionnaire (NPQ) at the end of part A and over time
Change from baseline in the Difficulty Thinking Numerical Rating Scale (NRS) at the end of part A and over time
Change from baseline in Patient Global Impression of Severity (PGIS) scores at the end of part A and over time
Change from baseline in Patient Global Impression of Change (PGIC) scores at the end of part A and over time
Change from baseline in Clinical Global Impression of Severity (CGIS) scores at the end of part A and over time
Change from baseline in Clinical Global Impression of Change (CGIC) scores at the end of part A and over time
Change from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-Fatigue) scores at the end of part A and over time
Arms and interventions
Double-blinded treatment period (DBTP): Efgartigimod PH20 SCExperimental
Participants receiving efgartigimod PH20 SC during the double-blinded treatment period
Double-blinded treatment period (DBTP): Placebo PH20 SCPlacebo comparator
Participants receiving placebo PH20 SC during the double-blinded treatment period
Open-label treatment period (OLTP)Experimental
Participants receiving efgartigimod PH20 SC during the open-label treatment period
Biologicals: efgartigimod PH20 SC
Other: Placebo PH20 SC
Sites
3 sites in 1 country